Qinghua Wu

Dr. Qinghua Wu

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2016 in CardioVascular and Interventional Radiology
Verified
Journal Article
Open access
PDF file
QWQinghua Wu
Qinghua Wu
ZLZhuan Liu
Zhuan Liu
XZXianlan Zhao
Xianlan Zhao
CLCai Liu
Cai Liu
YWYanli Wang
Yanli Wang
ZCZhimin Chen
Zhimin Chen
Purpose To explore the efficacy and safety of prophylactic temporary balloon occlusion of the infrarenal abdominal aorta during caesarean for the management of patients with placenta praevia accreta. Methods Two hundred and sixty-eight cases of placenta praevia accreta from January 2012 to June 2015 were retrospectively reviewed. Group A included two hundred and thirty patients who underwent prophylactic temporary balloon occlusion of infrarenal abdominal aorta followed by caesarean section. Group B included thirty-eight patients who underwent caesarean without endovascular intervention. The parameters including operating room time, estimated blood loss, blood transfusion volume, PT (prothrombin time) during operation, days in the intensive care unit, and total hospital days were compared between the two groups. Results The operating room time, estimated blood loss, PT, the incidence of hysterectomy, blood transfusion volume, postpartum haemorrhage, and days in intensive care unit were lower in group A than in group B, with statistical significance (P < 0.05). There was no significant difference in the Apgar scores of the neonates and the incidences of thrombosis in lower limbs between the two groups (P > 0.05). No patient in the group with prophylactic temporary balloon occlusion of the infrarenal abdominal aorta was performed hysterectomy, while three patients in group B were performed hysterectomy because of uncontrollable haemorrhage. Conclusions The results indicate that prophylactic temporary balloon occlusion of infrarenal abdominal aorta followed by caesarean section is safe and effective to control intraoperative blood loss and greatly decreases the risk of hysterectomy in patients with placenta praevia accreta.

14 December 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JDJuan Du
Juan Du
HShuirong shi
huirong shi
FRFang Ren
Fang Ren
JWJing-Lu Wang
Jing-Lu Wang
QWQinghua Wu
Qinghua Wu
RZRuitao Zhang
Ruitao Zhang
This study was aimed at investigating whether metformin can reverse the resistance of ovarian cancer cells to cisplatin and exploring the underlying mechanism. Ovarian cancer cell proliferation in vitro was evaluated using a CCK-8 assay. The resistance index of platinum-resistant ovarian cancer cells was determined and cell cycle and apoptosis rate determined by annexin V/propidium iodide double-staining in CP70 cells. Western blotting was used to determine IGF1, IGF1R, AKT, p-IGF1, p-IGF1R, p-AKT, and MRP2 levels in cells treated with different concentrations of metformin and LY29400, an inhibitor of the insulin-like growth factor pathway. Changes in gene expression levels of MRP2, IGF1, IGF1R, and AKT were determined by fluorescence real-time quantitative PCR assay of CP70 cells treated with metformin. Tumors of human ovarian cancer cell lines CP70 and A2780 were established by subcutaneous transplantation of cells in nude mice and the effect of metformin on MRP2 expression and tumor inhibition assessed. The IC50 value of cisplatin in CP70 cells decreased significantly as metformin concentration increased (P < 0.05). The cell cycle distribution in CP70 cells changed with metformin treatment; the percentage of cells in the G0/G1 phase, as well as the natural apoptosis rate was significantly increased with metformin treatment (P < 0.05). IGF1, IGF1R, AKT p-IGF1, p-IGF1R, and p-Akt protein expression was enhanced dose-dependently with metformin, and was also significantly changed by treatment of CP70 cells with 0 mM metformin +10 mM LY294002. Moreover, changes in the expression of MRP2, IGF1, IGF1R, and AKT was metformin-concentration dependent, and was significantly different from that in the untreated control group (P < 0.05). In nude mice, the tumor volumes of the cisplatin-treated groups were significantly less than in the control group, and was further suppressed by co-treatment with cisplatin and metformin (P < 0.05), indicating that these 2 drugs had a synergistic effect on tumor inhibition. Metformin can improve the sensitivity of ovarian cancer CP70 cells to cisplatin in a concentration-dependent manner by activating the AKT signaling pathway, inhibiting the IGF1R signaling pathway, and reducing MRP2 expression.

27 June 2022 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
SYSaisai Yang
Saisai Yang
GYGuanghui Yao
Guanghui Yao
XCXin Chen
Xin Chen
HSHuirong Shi
Huirong Shi
CLChihhong Lou
Chihhong Lou
QWQinghua Wu
Qinghua Wu
Nephrolithiasis is not common in children, but the incidence is gradually increased in these years. Urinary tract malformations, urinary infection, dietary habits, geographic region and genetic factor are involved in the etiology of nephrolithiasis. For the affected child, it is especially important to elucidate the etiology, which may provide an accurate diagnosis, a personalized therapy and effective follow-up strategy. Here to seek the etiology of a ten-year-old boy incidentally found with nephrolithiasis, next generation sequencing (NGS) including a panel with 248 genes involved in hereditary kidney diseases was performed for the boy and identified two mutations of KCNJ1, c.89G > A (p.C30Y) and c.65G > T (p.R22M), and the later was a novel missense mutation originated from his father. The child was confirmed with type II Bartter syndrome (BS) caused by KCNJ1 mutations. Our study suggests that BS may be difficult to get diagnosed at an early stage based on clinical manifestations or biochemical laboratory tests, and NGS is an efficient way to determine the etiology and provide further treatment and guide fertility counseling for the affected family.

1 October 2025 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
SYSaisai Yang
Saisai Yang
HSHuirong Shi
Huirong Shi
SRShumin Ren
Shumin Ren
YCYibing Chen
Yibing Chen
XJXiaoqing Jin
Xiaoqing Jin
QWQinghua Wu
Qinghua Wu
This study systematically characterized the global burden of pregnancy loss from 1990 to 2021 and evaluated the association between inflammatory markers and pregnancy loss, aiming to reduce the risk of pregnancy loss. A comprehensive analysis was conducted, encompassing the incidence, deaths, disability-adjusted life years (DALYs), and years lived with disability (YLDs), across a total of 204 countries. This analysis was complemented by the implementation of joinpoint regression and ARIMA models, which were utilized to assess trends and projections. Additionally, inflammatory markers were analyzed in a cohort of 5,517 U.S. women. The association between inflammatory markers and pregnancy loss was assessed using survey-weighted multivariate logistic regression. Subsequently, restricted cubic spline (RCS) plots were utilized to explore the non-linear association between inflammatory markers and pregnancy loss. Subgroup analyses were conducted to further elucidate the effects of other covariates on the association between inflammatory markers and pregnancy loss. Globally, the incidence of pregnancy loss has been observed to decline at a rate of 1.5% per annum, with a concomitant decrease in mortality of 64.8% from 1990 to 2021. The regions exhibiting the highest-burden were those with a low socio-demographic index (SDI), with an average age-standardized incidence rate (ASIR) of 1,715.1 per 100,000. In contrast, High SDI regions demonstrated rates below 500 per 100,000. Projections indicate a continued global decline to 725.2 cases/100,000 by 2032, though High SDI regions may face rising rates (3.66% annually). A U-shaped association between neutrophil-to-lymphocyte ratio (NLR) and miscarriage risk was revealed by NHANES analysis, with moderate NLR levels (the third quartile-the fourth quartile) linked to reduced odds (OR: 0.75–0.76, p < 0.05). Subgroup analyses revealed stronger associations in women aged ≤ 35 years and those with a Body Mass Index (BMI) of 25–30 kg/m2. These findings challenge the notion of linear inflammatory risk, emphasizing immune homeostasis’s role in pregnancy maintenance. The study underscores persistent disparities in low-resource settings and advocates for integrating inflammatory markers into clinical risk stratification. Public health strategies must address inequities through targeted antenatal care, while high-income regions require interventions targeting delayed childbearing and metabolic health. This dual approach may mitigate the evolving global burden of pregnancy loss.

10 April 2020
Verified
Journal Article
Closed access
QWQinghua Wu
Qinghua Wu
SYSaisai Yang
Saisai Yang
CWCan Wang
Can Wang
HSHuirong Shi
Huirong Shi
XKXiangdong Kong
Xiangdong Kong
PSPanlai Shi
Panlai Shi

10 February 2019
Verified
Journal Article
Closed access
QWQinghua Wu
Qinghua Wu
XMXiyang Ma
Xiyang Ma
XKXiangdong Kong
Xiangdong Kong
HSHuirong Shi
Huirong Shi
ZCZhengguang Chen
Zhengguang Chen
MJMiao Jiang
Miao Jiang